SPRO Stock Analysis: Buy, Sell, or Hold?
SPRO - Spero Therapeutics, Inc. Common Stock
$2.15
-0.06 (-2.71%)
▼
5d:
-26.12%
30d:
-20.07%
90d:
-8.51%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When SPRO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SPRO is down 26.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SPRO is down 26.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$7.51
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.66
53.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRO is currently trading at $2.15, which is considered oversold relative to its 30-day fair value range of $2.49 to $2.92. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.2) compared to its historical average (8.0). Remarkably, the market is currently pricing in an annual earnings decline of 26.2% over the next few years. This pessimistic expectation contrasts with the company's recent 75.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SPRO is in a strong uptrend. The price is currently testing key support at $2.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+86.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRO is in a strong uptrend. The price is currently testing key support at $2.52. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $4.00 (+86.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.49 -
$2.92
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.0% below Wall St target ($4.00)
- WARNING: Recommendation downgraded due to -26.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.49 -
$2.92
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.52
Resistance Level
$3.08
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.21
Wall Street Target
$4.00
(+86.0%)
Revenue Growth (YoY)
-95.6%
Earnings Growth (YoY)
75.3%
Profit Margin
24.9%
Valuation Discount vs History
-26.2% cheaper
PE vs Historical
3.2 vs 8.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.2%
(market-implied from PE analysis)
1-Year Target
$1.94
(-10%)
2-Year Target
$1.74
(-19%)
3-Year Target
$1.57
(-27%)
3-Yr Target (if PE normalizes)
(PE: 3→8)
$3.91
(+82%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (8x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 8.33 | Current EPS (TTM): $0.27
Bull Case
$4.95
(+124%)
Analyst growth 100.0%, PE expands to 9.2
Base Case
$4.50
(+104%)
Market implied 100.0%, PE stable at 8.3
Bear Case
$1.53
(-31%)
Severe decline -20.0%, PE contracts to 7.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.2 to 8.0
Stabilization Target:
$5.36
(+149.3%)
PE Expansion Potential:
+149.3%
Share & Embed Analysis
Last updated: June 23, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Esther Rajavelu
SELL
87917 shares
2026-02-06
Esther Rajavelu
SELL
18442 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
